These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9480308)

  • 1. [Emerging infectious diseases--E coli O157 infections].
    Nagayama K; Kodama T; Honda T
    Nihon Naika Gakkai Zasshi; 1997 Nov; 86(11):2046-51. PubMed ID: 9480308
    [No Abstract]   [Full Text] [Related]  

  • 2. [Enterohemorrhagic Escherichia coli infection].
    Nakayama K; Sato T
    Nihon Rinsho; 2004 May; 62 Suppl 5():472-7. PubMed ID: 15197966
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.
    Johnson KE; Thorpe CM; Sears CL
    Clin Infect Dis; 2006 Dec; 43(12):1587-95. PubMed ID: 17109294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features of enterohemorrhagic E. coli gastrointestinal infection].
    Igarashi T
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():581-5. PubMed ID: 16523959
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.
    Nelson JM; Griffin PM; Jones TF; Smith KE; Scallan E
    Clin Infect Dis; 2011 May; 52(9):1130-2. PubMed ID: 21467017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enterohemorrhagic Escherichia coli and its infection: from 1977 to 1995].
    Takede Y
    Nihon Rinsho; 1997 Mar; 55(3):635-40. PubMed ID: 9086772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
    Karmali MA
    J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691
    [No Abstract]   [Full Text] [Related]  

  • 9. Escherichia coli O157 in Somerset.
    Commun Dis Rep CDR Wkly; 1998 May; 8(19):167. PubMed ID: 9635338
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidemiology, pathogenesis and therapeutic modalities in hemolytic-uremic syndrome.
    Zimmerhackl LB
    Kidney Blood Press Res; 1998; 21(2-4):290-2. PubMed ID: 9762861
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemolytic uremic syndrome: an emerging health risk.
    Razzaq S
    Am Fam Physician; 2006 Sep; 74(6):991-6. PubMed ID: 17002034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Shiga toxin production by Escherichia coli strains and antibiotics].
    Sidorenko SV
    Antibiot Khimioter; 2001; 46(5):3-5. PubMed ID: 11558452
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome.
    Goldwater PN
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):653-63. PubMed ID: 17678428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E. coli, antibiotics and hemolytic-uremic syndrome in children.
    Farquhar D
    CMAJ; 2000 Aug; 163(4):438. PubMed ID: 10976267
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between hemolytic uremic syndrome and verotoxin-producing strains of E. coli.
    Jure MA; de Saab OA; de Castillo MC; Sesma F; Miceli S; Zamora AM; de Ruiz Holgado AP; de Nader OM
    Rev Latinoam Microbiol; 1998; 40(1-2):1-8. PubMed ID: 10932728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimotility agents and E. coli infection.
    Tarr PI; Christie DL
    CMAJ; 1999 Apr; 160(7):984, 986. PubMed ID: 10207332
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
    Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
    Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Verotoxin induced hemolytic uremic syndrome: pathophysiology of neurological involvement].
    Takagi C; Naruse T
    Nihon Rinsho; 1997 Mar; 55(3):731-5. PubMed ID: 9086789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enterohemorrhagic Escherichia coli--infection and a hemolytic uremic syndrome].
    Helminen M; Wisakanto KL; Raisio M; Baer M
    Duodecim; 1998; 114(3):229-32. PubMed ID: 10895492
    [No Abstract]   [Full Text] [Related]  

  • 20. [Escherichia coli verotoxin (relationship between verotoxin produced by E. coli O157: H7 and HUS)].
    Matsunaga T; Komoda T
    Nihon Rinsho; 1999 Nov; 57 Suppl():172-5. PubMed ID: 10635805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.